Although most gastroenterologists feel that store-brand and branded treatments are equivalent, most continue to recommend branded products for gastroesophageal reflux disease and chronic constipation, according to two studies presented at the annual Digestive Disease Week, held from May 3 to 6 in Chicago.
Patients with IBS-D in two phase II trials of eluxadoline experienced sustained improvements in abdominal pain and bowel symptoms at 26 weeks of treatment, with mild side effects.
Patients with celiac disease treated with larazotide acetate experienced improvements in GI symptoms and non-GI symptoms such as headache and fatigue, as well as significant reductions in the number of symptomatic days.
Results from the PEARL-II study show treatment-experienced patients with hepatitis C genotype 1b achieved SVR rates of greater than 96% when treated with a combination of ABT 450 with ritonavir, co-formulated with ombitasvir and dasabuvir, without the need for ribavirin.
Uma Mahadevan, MD, co-medical director of clinical research at the UCSF Center for Colitis and Crohn’s disease, discusses how gastroenterologists should handle primary care and pregnancy issues in inflammatory bowel disease patients.
Although the treatment options for patients with both the hepatitis C virus (HCV) and HIV are mostly the same, response rates can be lower, according to Richard Sterling, MD.